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1632Objective: INTERMACS is a registry of mechanical circulatory support devices sponsored by the National
Institutes of Health. This analysis uses INTERMACS data to define the time course, incidence, and outcome
of infection adverse events focusing on the first 3 months after implant.
Methods: Patients entered into INTERMACS from June 23, 2006, to September 30, 2008, were analyzed. Preim-
plant data (demographics, hemodynamics, and laboratory values), infection adverse events, and other outcomes
were recorded. Infection adverse events were analyzed to compare infection rates in subgroups of patients and
define risk factors for death.
Results: The analysis was confined to pulsatile mechanical circulatory support devices. A total of 593 patients
from 88 institutions were entered. Infection was a relatively common event within the first 3 months of implant
and was significantly (P ¼ .005) more common in patients with biventricular assist devices than in patients
with left ventricular assist devices, although the prevalence of infection equalized in months 4 to 12. Infection
had a significant adverse effect on survival. Independent risk factors for death included support with a biventricular
assist device, older age, severity of patient illness implantation of the device (INTERMACS level 1), and higher
blood urea nitrogen.
Conclusions: Infection remains a relatively frequent adverse event and is associated with decreased survival.
Interventions to prevent infection that focus on the preoperative and immediate postoperative periods are the
ones most likely to achieve success by diminishing the incidence of infection during the initial 3 months after
implantation. Rotary (continuous-flow) pumps are expected to have lower infection rates, but this remains to
be seen. (J Thorac Cardiovasc Surg 2010;139:1632-6)Supplemental material is available online.The Interagency Registry for Mechanically Assisted Circu-
latory Support (INTERMACS) is a national registry for pa-
tients who receive a durable mechanical circulatory support
device (MCSD) for advanced medically refractory heart fail-
ure.1 Only MCSDs approved by the United States Food and
Drug Administration (FDA) are included in this registry. A
list of the MCSDs represented in this analysis is presented in
Appendix E1.
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The Journal of Thoracic and Cardiovascular SurThis has proven to be the case, as shown in individual center
experiences and multicenter studies,3-9 although advances in
engineering, patient selection, and patient management are
improving patient outcomes.10-13
Before initiating data collection for INTERMACS, a col-
laborative group of physicians, nurses, members of the reg-
ulatory community, including the FDA, and representatives
from industry defined a list of adverse events (AEs) for this
prospectively gathered database. Definitions for the AEs are
available from the INTERMACSWeb site (www.intermacs.
org). The present study focuses on an analysis of infection
AEs as listed in Appendix E2 during a defined period of
time when essentially all implants of FDA-approved pumps
were pulsatile devices. The purpose of the analysis was to
define the time course, incidence, outcome, and risk factors
for infection inMCSD recipients. The information will serve
as a basis for the development of prophylactic and therapeu-
tic measures aimed at diminishing the incidence and impact
of infection in patients with MCSDs. Moreover, it will be
possible to compare the rates and consequences of infection
for pulsatile and continuous-flow (rotary) pumps as
continuous-flow devices receive FDA approval.
METHODS
Prospectively gathered data were collected from MCSD implants that
took place from June 23, 2006, to September 30, 2008 (n ¼ 593 patients).gery c June 2010
Abbreviations and Acronyms
AE ¼ adverse event
BiVAD ¼ biventricular assist device
FDA ¼ Food and Drug Administration
INTERMACS ¼ Interagency Registry for
Mechanically Assisted
Circulatory Support
MCSD ¼ mechanical circulatory support
device
VAD ¼ ventricular assist device
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XThe numbers and location (left ventricular assist device [VAD] vs biventric-
ular assist device [BiVAD]) for devices implanted during this time are listed
in Table E1 along with the prevalence of infection AEs. Total artificial heart
implants, isolated rotary VADs (ie, MicroMed DeBakey Child left VAD;
MicroMed Technology, Inc, Houston, Tex), and isolated right VAD im-
plants were uncommon relative to pulsatile BiVAD and left VAD implants.
Isolated right VAD, rotary VAD, and total artificial heart implants were
therefore not included in the present analysis of infection AEs. The indica-
tion for VAD use was determined before implant and was classified as
bridge to transplantation, destination therapy (ie, a permanent implant in
a patient not considered to be a candidate for transplantation), or bridge
to recovery of the native heart.
During the period of this analysis, there were 88 institutions entering
data. Participating centers are listed on the INTERMACS Web site. This
list changes over time as centers are removed and added to the actively en-
rolling institutions.
Data were transmitted from sites using a Web-based system to a secure
server administered by the United Network for Organ Sharing. The study
sites and the central data processing and analyzing institutions received in-
stitutional review board approval before initiating the collection of data. The
data coordinating center at University of Alabama at Birmingham provided
data analysis. The variables specific to infection included the microbial eti-
ology (bacterial, fungal, viral, protozoan, or unknown), the site of infection
(if known), a determination of whether the infection was patient-related or
device-related, and the therapy used for infection (drug only, drug and sur-
gical, surgical only, or unknown).
The specific data gathered to describe patient demographics, hemodynam-
ics, laboratory values, and other outcome events can be found at the INTER-
MACSWeb site. The INTERMACS data were checked for completeness by
the central collection facility (theUnitedNetwork forOrgan Sharing).Values
that fell outside predetermined limits were validated with their site of origin.
AE reporting forms are reviewed by two physicians from the INTERMACS
community. Differences of opinion between the reviewers were adjudicated
by members of the INTERMACS AE committee before final decisions were
made on the classification of individualAEs. Source documentswere not rou-
tinely available for verification or adjudication.
Actuarial depictions of data were used to compare subgroups for infec-
tion rates and survival. It was recognized that repeated infections can occur
in individual patients. Therefore, the time to first infection was analyzed
along with cumulative infection AEs within the population of MCSD recip-
ients. A multivariable analysis was performed to define preimplant risk fac-
tors that were independent predictors for cumulative infections. The
variables included in the analysis were patient demographics, hemodynam-
ics, patient medical history, INTERMACS patient profile (severity of illness
before implant), device strategy (left VAD versus BiVAD), and blood
chemistry data. Hazard ratios were defined in addition to P values for these
independent risk factors.The Journal of Thoracic and CarRESULTS
A total of 593 patients were prospectively entered into the
INTERMACS database between June 23, 2006, and Sep-
tember 30, 2008. These patients came from 88 institutions
and were predominantly white men with an average age at
implant of 51.5 years and a range of 19.8 to 79.0 years
(Table E2). The prevalence of infection was similar for left
VADs and BiVADs and was in line with the prevalence of
infection previously reported for single institution and mul-
ticenter trials.14 The cumulative infection rates were similar
between men and women, but the infection rate was signif-
icantly influenced by age (Figure 1). The majority (87%) of
infections were bacterial in origin with smaller percentages
of fungal (9%), viral (1%), protozoal (0.3%), or unknown
(2%) infections.
The most common preimplant INTERMACS level was
level 1 (critical cardiogenic shock) and was reported for
42% of implanted patients. Lesser degrees of patient illness
and acuity were seen in the remaining patients, although
38% were listed as INTERMACS level 2 (ie, progressive
decline). The INTERMACS classification had a significant
adverse affect on cumulative infection episodes across the
initial 18 months after implant (Figure 2). This difference
was most prominent during the first 3 months of implant,
when level 1 patients had nearly 1.5 infection episodes per
patient whereas levels 2 through 7 had less than 1.0 infection
episodes per patient. An increase in infections episodes was
seen between months 18 and 24 for INTERMACS levels 2
and levels 4 through 7 (Figure 2).
Infection episodes were most commonly related to posi-
tive blood cultures (32% of all infections) or driveline infec-
tions (21% of all infections) (Table E3). Of note, 15% of
reported infections were from other sources identified in
text fields and were not included in these analyses. Device-
related infections (driveline, pump pocket, and pump inte-
rior) occurred in 194 of 682 (28.4%) of infection episodes.
The cumulative infection rate per patient was significantly
higher in patients who received BiVAD support as com-
pared with isolated left VAD support (Figure 3). Infection
episodes in patients with BiVAD support were more com-
mon in the first 3 months of support as compared with the
4- to 6-month, 7- to 9-month, and 10- to 12-month intervals
after implant (Figure E1). By the 10- to 12-month time
frame, the rate of infection for left VADs was increasing.
Infection had a significant adverse affect on survival, and
patients with an infection AE during the first month after im-
plant had significantly worse survival than patients who did
not have their first infection AE until the second or third
month after implant (Figure 4). Moreover, patients requiring
BiVAD support who had an infection within the first 3
months after implant had significantly worse survival than
patients who had isolated left VAD support and an infection
AE within the first 3 months of support (Figure 5).diovascular Surgery c Volume 139, Number 6 1633
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FIGURE 1. Cumulative infection events by age (left ventricular assist
device only).
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FIGURE 3. Cumulative infections after mechanical circulatory support
device implant. BiVAD, Biventricular assist device; LVAD, left ventricular
assist device.
Cardiothoracic Transplantation Holman et al
T
XThe multivariable analysis of preimplant risk factors for
cumulative postimplant infections showed that use of Bi-
VADs, older age, INTERMACS level 1 (critical cardiogenic
shock), and higher blood urea nitrogen values were all
predictors of a higher cumulative number of infection AEs
(Table E4). Use of BiVADs, INTERMACS level 1, and
higher blood urea nitrogen values can be viewed as indica-
tors of more advanced heart failure or acute decompensation
of chronic heart failure. The hypothesis of whether conver-
sion to a higher INTERMACS level before implant via in-
tensive preimplant medical management is intriguing, but
it could not be evaluated from the data collected for this
analysis.
DISCUSSION
Device reliability, thromboembolic complications, and in-
fection were identified during the early phase of MCSD de-0.0
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FIGURE 2. Cumulative infection events by INTERMACS patient profile
(left ventricular assist device only).
1634 The Journal of Thoracic and Cardiovascular Survelopment as the most likely obstacles to the successful use
of MCSDs in prolonging survival and improving the quality
of life for patients with advanced heart failure.2 These predic-
tions proved correct, although continued improvements in de-
vice design, patient selection, and patient management
promise to diminish their incidence and importance.10-13
During the era of this study, nearly all of the devices im-
planted were pulsatile pumps rather than continuous-flow
(rotary) pumps. Pulsatile MCSDs are larger than rotary
MCSDs. In addition, the implanted pulsatile pumps in this
analysis have larger diameter and more rigid drivelines
than rotary pumps to accommodate a channel that vents air
displaced by the pumping sac. These considerations may in-
fluence the incidence and severity of device-related infec-
tions (eg, pump pocket and driveline infections). On the
basis of experiences from single center and individual device0
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Xtrials published to date for rotary pumps, INTERMACSmay
document a lower incidence of infection AEs for rotary
pumps as their results enter the INTERMACS Registry.
The Randomized Evaluation of Mechanical Assistance
for the Treatment of Congestive Heart Failure (REMATCH)
Trial showed that an implanted pulsatile left VAD (Heart-
Mate I; Thoratec Corporation, Pleasanton, Calif) provided
superior survival (48% reduction in risk of death) as com-
pared with optimal medical management for patients with
advanced heart failure. However, infection AEs were rela-
tively common in this group of patients (0.60 events/
patient-year for sepsis; 0.39 events/patient-year for local in-
fection). There was a 28% (95% confidence interval 15%–
38%) probability of left VAD infection within 3 months af-
ter implant, and sepsis was the most common mode of death
in patients who were randomized to MCSD therapy (17/41
patients).15 Further examination of the REMATCH Trial
in a post hoc analysis of infection complications showed
that the instantaneous risk (ie, hazard) for sepsis was highest
within the first 30 days after device implant.16 No late rising
phase of risk was identified in this study, although many of
the patients required device replacement between 18 and 24
months after implant. The post hoc analysis showed an ad-
verse effect of sepsis on survival with 60% 1-year and
38% 2-year survival for left VAD patients without sepsis
versus a 39% 1-year and 8% 2-year survival for left VAD
patients with an episode of sepsis (P ¼ .06). Interestingly,
a subgroup of hospitals in this multicenter trial experienced
fewer episodes of sepsis than other hospitals independent of
other risk factors (P ¼ .012; 95% confidence interval 1.3–
7.0), suggesting that local surgical and nursing practice
may have important effects on infection rate and survival
for patients with implanted pulsatile left VADs for the indi-
cation of destination therapy.The Journal of Thoracic and CarThe present analysis of the INTERMACS database found
that infection AEs were most common within the first 3
months after implant and that the presence of infection had
a statistically significant negative influence on survival. Fur-
thermore, it appears that certain subgroups of patients (eg,
patients with critical cardiogenic shock) are at highest risk
for infection AEs. This is similar to prior analyses of the IN-
TERMACS database that showed that indicators of right
heart failure (eg, requirement for BiVAD support, hepatic
dysfunction characterized by elevated bilirubin or ascites)
and acute circulatory decompensation (eg, INTERMACS
level 1) were associated with death.17 However, it also ap-
pears that after the initial 3 months of implant the difference
in cumulative infections diminishes for BiVAD patients as
compared with the left VAD recipients, perhaps because
those patients with preoperative biventricular failure achieve
a compensated state on BiVAD support.
Driveline infectionswere a relatively common event (21%
of infection AEs). It is possible that eliminating the need for
a percutaneous driveline will substantially diminish the num-
ber of infection AEs in MCSD recipients. Obstacles to the
elimination of the driveline include the engineering complex-
ity and reliability demands for fully implanted MCSDs that
rely on transcutaneous energy transmission systems and
that require implanted controllers and batteries. Fully im-
planted assist devices such as the formally available Lion
Heart (Arrow International, Inc, Reading, Pa) may diminish
the incidence and consequences of sepsis and device-
related infections, as suggested by Pae and coinvestigators18
in the multicenter Clinical Utility Baseline Study (CUBS)
Trial. However, the engineering challenges and costs for
fully implanted pulsatile systems remain formidable. Smaller
diameter and more supple drivelines may help in the battle
against infection at the percutaneous insertion site. Such
modifications are feasible for rotary pump designs that do
not require external venting of air. As driveline designs are
optimized or eliminated and other patient management tech-
niques advance, INTERMACSwill be useful for quantifying
changes in the incidence and consequences of infection.
The cumulative number of infections that occur within the
first 3 months of implant and the influence of these infections
on patient survival suggest that measures to diminish early
infections are potentially fruitful ways for increasing sur-
vival and improving the quality of life for patients with du-
rable MCSDs. Examples include efforts at stabilizing the
driveline to optimize tissue in-growth and close follow-up
of patients after hospital discharge to aggressively treat
driveline infections or local non-device infections at the
earliest possible time.
The referral of patients for MCSD support before the on-
set of critical cardiogenic shock and biventricular failure are
suggested by the present analysis as ways to improve sur-
vival. This is corroborated by earlier analyses of INTER-
MACS data that defined markers for the onset of rightdiovascular Surgery c Volume 139, Number 6 1635
Cardiothoracic Transplantation Holman et al
T
Xventricular failure as risk factors for death (eg, ascites, in-
creased bilirubin, and increased blood urea nitrogen). Inas-
much as patients are often in cardiogenic shock when
initially evaluated for MCSD support, improving the pa-
tient’s condition with a period of intense medical manage-
ment before VAD implant may also be of some benefit.
Surgical (intraoperative) improvements that may diminish
the incidence of early postimplant infections include the use
of continuous-flow (rotary) pumps that can be implanted
more expeditiously than larger pulsatile pumps9,19,20 and
the use of less invasive techniques, especially in patients
with prior cardiac operations.21 Skull fixation for the trans-
cutaneous power lead as reported by Westaby and associ-
ates22 is another possibility for decreasing percutaneous
driveline infections, although this technique has not yet
been used in a large number of patients.
In the rapidly evolving field of mechanical circulatory
support, the INTERMACS Registry is an important tool
for analyzing data that critically evaluate adverse outcomes,
such as infection, and for suggesting future clinical research
to expedite clinically meaningful improvements with VAD
support. Clinical research to evaluate interventions that de-
crease the incidence of preoperative and immediate postop-
erative infections is critical to improving outcomes and cost
for patients treated with mechanical circulatory support.References
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Appendix E2. INTERMACS Definitions for Major
InfectionE2
A clinical infection accompanied by pain, fever, drainage,
and/or leukocytosis that is treated by antimicrobial agents
(nonprophylactic). A positive culture from the infected site
or organ should be present unless strong clinical evidence in-
dicates the need for treatment despite negative cultures. The
general categories of infection are listed below:
Localized Nondevice Infection
Infection localized to any organ system or region (eg, me-
diastinitis) without evidence of systemic involvement (see
sepsis definition), ascertained by standard clinical methods
and either associated with evidence of bacterial, viral, fungal
or protozoal infection, and/or requiring empirical treatment.
Percutaneous Site and/or Pocket Infection
A positive culture from the skin and/or tissue surrounding
the driveline or from the tissue surrounding the external
housing of a pump implanted within the body, coupled
with the need to treat with antimicrobial therapy, when there
is clinical evidence of infection such as pain, fever, drainage,
or leukocytosis.
Internal Pump Component, Inflow, or Outflow Tract
Infection
Infection of blood-contacting surfaces of the left VAD
documented by positive site culture (There should be
a separate data field for paracorporeal pump that describes
infection at the percutaneous cannula site, eg, Thoratec
PVAD).
Sepsis
Evidence of systemic involvement by infection, mani-
fested by positive blood cultures and/or hypotension.
E-References
E1. INTERMACS Durable Devices Included in Database. Available at: http://www.
uab.edu/ctsresearch/intermacs/Document%20Library/Appendix%20K%20%
20Device%20Brand%20List,%20FINAL,%2010-30-08.doc 2009.
E2. INTERMACS Infection Adverse Event Definition. Available at: http://www.uab.
edu/ctsresearch/intermacs/Document%20Library/Appendix%20A%20-Adverse
%20Event%20Definitions_V2.3.doc 2009.
Appendix E1. Durable mechanical circulatory assist devices for
INTERMACS June 23, 2006, through September 30, 2008E1
Company Device Position
Abiomed, Inc AbioCor TAH TAH
Micromed Technology, Inc MicroMed DeBakey VAD–Child L
SynCardia Systems, Inc SynCardia CardioWest TAH
Thoratec Corporation HeartMate II LVAS (April 2008) L
HeartMate IP L
HeartMate VE L
HeartMate XVE L
Thoratec IVAD L/R
WorldHeart, Inc NovaCor PC L
NovaCor PCq L
Approved durable devices (potential for patient discharge): These devices should be
entered into INTERMACS except in rare circumstances in which a patient with an
approved device is in the control arm of an FDA-approval study.
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FIGURE E1. Infection rates in the first year after implantation of mechan-
ical circulatory support device. BiVAD, Biventricular assist device; LVAD,
left ventricular assist device.
Table E1. Sites of infection during MCSD support (INTERMACS
June 23, 2006–September 30, 2008): Primary adult pulsatile implants
Infections
Device side Patients Events (patients) Prevalence (%)
LVAD 465 563 (190) 41
BiVAD 128 119 (54) 42
Total 593 682 (244)
LVAD, Left ventricular assist device; BiVAD, biventricular assist device.
Table E3. Sites of infection on pulsatileMCSD support (INTERMACS
June 23, 2006–September 30, 2008): Primary adult pulsatile implants
Location* n % of 682
Pump-related
Driveline 140 21
Pump pocket 51 7
Pump interior 3 0.4
Line sepsis 46 7
Mediastinum 18 3
Peripheral wound 22 3
Pulmonary 116 17
Gastrointestinal 39 6
Urinary tract 111 16
Positive blood cultures 218 32
Other 100 15
Unknown 7 1
Total 682
*More than one location can exist for one identified infection.
Table E2. Gender, race, and age at implant (INTERMACS June 23,
2006–September 30, 2008): Primary adult pulsatile implants
Gender
Male 479 (80.8)
Female 114 (19.2%)
Race
White 425 (71.7%)
African American 126 (21.2%)
Other 42 (7.1%)
Age at implant (y)
Mean 51.5
Range 19.8–79.0
Table E4. Preimplant risk factors for cumulative infections
(INTERMACS June 23, 2006–September 30, 2008): Primary adult
pulsatile implants)
Risk factor Hazard ratio P value
BiVAD 1.35 .04
Age (older) 1.25* <.0001
INTERMAC level 1 2.34 <.0001
Blood urea nitrogen (higher) 2.26y <.0001
BiVAD, Biventricular assist device. *The hazard ratio is calculated for a 10-year
increase in age. yThe hazard ratio is calculated for a 50-unit increase in blood urea
nitrogen.
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